Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyzable (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P less than 0.001) and the ND urinary level (0.94 +/- 0.20, P less than 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 +/- 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.
D000230:Adenocarcinoma / Q000378:metabolism* / Q000652:urine; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D003094:Collagen / Q000378:metabolism; D003404:Creatinine / Q000652:urine; D003956:Dialysis; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000652:urine; D011877:Radionuclide Imaging; D013997:Time Factors
D003094:Collagen; D003404:Creatinine; D006909:Hydroxyproline